PMID- 20818792
OWN - NLM
STAT- MEDLINE
DCOM- 20100924
LR  - 20211028
IS  - 1531-8249 (Electronic)
IS  - 0364-5134 (Print)
IS  - 0364-5134 (Linking)
VI  - 68
IP  - 3
DP  - 2010 Sep
TI  - JC virus persistence following progressive multifocal leukoencephalopathy in 
      multiple sclerosis patients treated with natalizumab.
PG  - 384-91
LID - 10.1002/ana.22137 [doi]
AB  - JC virus (JCV) DNA in the cerebrospinal fluid (CSF) provides the laboratory 
      confirmatory diagnosis of progressive multifocal leukoencephalopathy (PML) in 
      patients whose clinical symptoms and magnetic resonance imaging findings are 
      consistent with PML.The Laboratory of Molecular Medicine and Neuroscience (LMMN), 
      National Institute of Neurological Disorders and Stroke (NINDS), National 
      Institutes of Health (NIH), made the confirmatory laboratory diagnosis in 35 
      multiple sclerosis (MS) patients treated with natalizumab. Thirteen patients had 
      3 or more CSF samples taken from weeks to months following PML diagnosis. Seven 
      of the 13 patients demonstrated persistence of JCV DNA in the CSF even though all 
      patients experienced immune reconstitution inflammatory syndrome (IRIS), 11 
      patients had plasma exchange, and 2 had immunoabsorption. Specific anti-JCV 
      antibody was measured in plasma/sera samples from 25 of the 35 patients. Most of 
      the samples showed moderate to high or rising antibody levels from the time of 
      PML diagnosis. However, plasma from 1 patient at or near the time of PML 
      diagnosis had a titer considered seronegative and 2 other plasma samples from 
      patients had titers considered at baseline for seropositivity. In several PML 
      cases, viral persistence and neurological deficits have continued for several 
      years, indicating that once initiated, JCV infection may not entirely clear, even 
      with IRIS.
FAU - Ryschkewitsch, Caroline F
AU  - Ryschkewitsch CF
AD  - Laboratory of Molecular Medicine and Neuroscience, National Institute of 
      Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 
      20892, USA.
FAU - Jensen, Peter N
AU  - Jensen PN
FAU - Monaco, Maria Chiara
AU  - Monaco MC
FAU - Major, Eugene O
AU  - Major EO
LA  - eng
GR  - Z01 NS001983-37/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PL  - United States
TA  - Ann Neurol
JT  - Annals of neurology
JID - 7707449
RN  - 0 (Antibodies)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (DNA, Viral)
RN  - 0 (Natalizumab)
SB  - IM
CIN - Ann Neurol. 2011 Feb;69(2):429-30; author reply 430-1. PMID: 21246607
MH  - Antibodies/blood
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - DNA Copy Number Variations/physiology
MH  - DNA, Viral/blood/*cerebrospinal fluid
MH  - Enzyme-Linked Immunosorbent Assay/methods
MH  - Female
MH  - Humans
MH  - JC Virus/*immunology
MH  - Leukoencephalopathy, Progressive Multifocal/*drug 
      therapy/*etiology/metabolism/virology
MH  - Longitudinal Studies
MH  - Male
MH  - Multiple Sclerosis/cerebrospinal fluid/*complications/virology
MH  - Natalizumab
PMC - PMC3739486
MID - NIHMS219570
EDAT- 2010/09/08 06:00
MHDA- 2010/09/25 06:00
PMCR- 2013/08/09
CRDT- 2010/09/07 06:00
PHST- 2010/09/07 06:00 [entrez]
PHST- 2010/09/08 06:00 [pubmed]
PHST- 2010/09/25 06:00 [medline]
PHST- 2013/08/09 00:00 [pmc-release]
AID - 10.1002/ana.22137 [doi]
PST - ppublish
SO  - Ann Neurol. 2010 Sep;68(3):384-91. doi: 10.1002/ana.22137.